Clinical utility of TSH receptor antibody determination
It is generally accepted that antibody to thyrotropin receptor (TRAb) with stimulatory activity is the major pathogenetic factor in Graves' disease. Despite that, determination of these autoantibodies is not a routine analysis in clinical practice. Aim of this paper is analyzing and presenting...
Main Authors: | Paunković Nebojša, Paunković Džejn |
---|---|
Format: | Article |
Language: | English |
Published: |
Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor
2011-01-01
|
Series: | Medicinski Glasnik Specijalne Bolnice za Bolesti Štitaste Žlezde i Bolesti Metabolizma "Zlatibor" |
Subjects: | |
Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/1821-1925/2011/1452-09231141066P.pdf |
Similar Items
-
Comparison of Five TSH-Receptor Antibody Assays in Graves’ disease: results from an observational pilot study
by: Tristan Struja, et al.
Published: (2019-04-01) -
Comparison of two different TSH-receptor antibody assays: A clinical practice study
by: Mathé van Balkum, et al.
Published: (2023-12-01) -
Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation
by: Silvestre Ramona A., et al.
Published: (2021-03-01) -
Characterization, treatment preferences, and outcomes of 390 Egyptian Graves’ disease patients: a retrospective study
by: Tamer Mohamed Elsherbiny
Published: (2023-08-01) -
Evaluation of the Abbott Alinity i Thyroid-Stimulating Hormone Receptor Antibody (TRAb) Chemiluminescent Microparticle Immunoassay (CMIA)
by: Deborah J. W. Lee, et al.
Published: (2023-08-01)